Italiano | English
This group will be fully involved in design, development and execution of clinical trials with new drugs or a combination of old and new drugs previously tested in vitro and resulted useful in controlling the growth of neoplastic cells of patients affected by Ph-negative Myeloproliferative Neoplasms. Furthermore, we will search novel possible therapeutic targets to be validated for the individuation of molecules interesting as new drugs. In patients enrolled in these trials, we will study molecular, cellular, or phenotypic characteristics we have discovered as being associated with these diseases, and that could serve as a suitable biomarker of response. These putative biomarkers of therapeutic response should be verified in larger patient series.
(click on names for curriculum vitae - PDF documents, 10-20 kB - available after you install Adobe Reader )